

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

EXPIRATION OF THE TERM OF OFFICE OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The board of directors (the “**Board**”) of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”) recently received written resignation letters from Mr. Tian Qiusheng (“**Mr. Tian**”) and Mr. Wong Kam Wa (“**Mr. Wong**”), both independent non-executive directors. Mr. Tian and Mr. Wong have both served as independent non-executive directors of the Company since 15 October 2019. As at 15 October 2025, they will have served as independent non-executive directors of the Company for six consecutive years. According to the Measures for the Administration of Independent Directors of Listed Companies and the Articles of Association and other relevant regulations, the term of office of an independent director shall not exceed six years. Therefore, Mr. Tian and Mr. Wong submitted written resignation letters to the Board. Mr. Tian applied to resign from the positions of independent non-executive director of the Company’s eleventh session of the Board, member of the Audit Committee, Chairman of the Remuneration and Assessment Committee, member of the Nomination Committee and member of the Environmental, Social and Governance Committee. Mr. Wong has applied to resign from his position as a member of the Environmental, Social and Governance Committee.

According to the relevant provisions of the Terms of Reference of the Audit Committee under the Board, Terms of Reference of the Remuneration and Assessment Committee under the Board, Terms of reference of the Environmental, Social and Governance Committee of the Board and etc., the departure of Mr. Tian and Mr. Wong upon the expiration of their terms will result in: (i) the number of members of the Audit

Committee being less than three, falling below the minimum requirement stipulated under Rule 3.21 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”); (ii) the number of members of the Remuneration and Assessment Committee being less than three, failing to meet the requirement under Rule 3.25 of the Hong Kong Listing Rules that the committee must be chaired by an independent non-executive director; and (iii) the number of members of the Environmental, Social and Governance Committee being less than five. In addition, Mr. Wong’s departure will result in the composition of the Board not satisfying the requirement of Rule 19A.18(1) of the Hong Kong Listing Rules, which requires a PRC issuer must have at least one of the independent non-executive directors must be ordinarily resident in Hong Kong.

To ensure the normal operation of the Board, until the Company’s general meeting of shareholders elects new independent non-executive directors, Mr. Tian and Mr. Wong will continue to perform their respective duties as independent non-executive directors and members of the special committees of the Board in accordance with relevant regulations such as the Articles of Association, the Measures for the Administration of Independent Directors of Listed Companies, and the Hong Kong Listing Rules. The Company will complete the election of new independent non-executive directors and members of the special committees of the Board as soon as possible in accordance with relevant regulations and statutory procedures.

Mr. Tian and Mr. Wong have both confirmed that they have no disagreement with the Board or the Company, and there are no matters in relation to their resignations that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

During their tenure as independent non-executive directors of the Company, Mr. Tian and Mr. Wong performed diligently and conscientiously and played an active role in promoting the Company’s standardized operations. The Board expresses its sincere gratitude to Mr. Tian and Mr. Wong for their contributions during their tenure.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
14 October 2025

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*